Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verve Therapeutics
Biotech
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
The patient who had two grade 3 side effects after receiving VERVE-101 was asymptotic, and lab abnormalities resolved within days.
Max Bayer
Apr 2, 2024 7:00am
Biotech insiders savor 49ers' latest victory in Super Bowl run
Jan 30, 2024 7:00am
Verve shows base editing works in humans—and sees stock sink
Nov 13, 2023 8:43am
Beam offloads Verve rights to Lilly for up to $600M
Oct 31, 2023 6:00am
FDA frees Verve's base editing therapy from clinical hold
Oct 23, 2023 6:30am
Lilly pays $60M for Verve's gene editing cardiovascular program
Jun 15, 2023 7:30am
